Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a 505(b)(2) program relying on literature plus a bridging study, biosimilar analytical similarity report is the evidence after a literature paper the 505(b)(2) package leans on getting retracted. RWE evidence-strategy director has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling close using biosimilar analytical similarity report.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. The population in biosimilar analytical similarity report is the one a literature paper the 505(b)(2) package leans on getting retracted named, so Proceed under protocol follows for this FDA Response and Labeling file. 2. The population in biosimilar analytical similarity report is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; Pause the pathway is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a literature paper the 505(b)(2) package leans on getting retracted before biosimilar analytical similarity report arrived; no new FDA Response and Labeling path. 4. Provenance on biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move the 505(b)(2) bridge is for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.